Human Apyrase to Disrupt Cancer Therapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43CA130192-01A2
Agency Tracking Number: CA130192
Amount: $196,745.00
Phase: Phase I
Program: SBIR
Awards Year: 2008
Solicitation Year: 2008
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
DUNS: 192266141
HUBZone Owned: Y
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 RIDONG CHEN
 (314) 608-6932
 RCHEN@NIDUSCENTER.COM
Business Contact
Phone: (314) 812-8054
Email: rchen@niduscenter.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, alone or in combination with aspirin, is effective in inhibiting experimental spontaneous metastasis in mice. PUBLI C HEALTH RELEVANCE:Human apyrase represents a highly promising therapy for cancer treatment. We will determine whether the targeted apyrase, alone or in combination with aspirin, is effective in inhibiting experimental metastasis in mice.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government